China Shineway Pharmaceutical Group Limited (HKG: 2877)

Market Cap	6.88B
Revenue (ttm)	4.52B
Net Income (ttm)	1.19B
Shares Out	755.40M
EPS (ttm)	1.57
PE Ratio	5.81
Forward PE	6.07
Dividend	0.58 (6.02%)
Ex-Dividend Date	Sep 10, 2024

Volume	170,000
Open	9.81
Previous Close	9.72
Day's Range	9.63 - 9.82
52-Week Range	7.22 - 10.76
Beta	0.84
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 28, 2025

About China Shineway Pharmaceutical Group

China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules in various therapeutic areas, including respiratory system disease, nervous system, digestive system disease, cardiovascular and cerebrovascular, orthopedics, pediat...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 3,436
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2877

Financial Performance

In 2023, China Shineway Pharmaceutical Group's revenue was 4.52 billion, an increase of 14.32% compared to the previous year's 3.95 billion. Earnings were 969.51 million, an increase of 34.14%.

Financial numbers in CNY